Thursday, 30 April 2020

Fragile X syndrome


The Fragile X syndrome is caused by a "fragile" site at the end of the long arm of the X-chromosome. It is a genetic disorder that manifests itself through a complex range of behavioural and cognitive phenotypes. It is the result of genetic mutation which varies considerably in severity among patients. Fragile X syndrome is the most common cause of inherited mental retardation. Although it is a X-linked recessive trait with variable expression and incomplete penetrance, 30% of all carrier women are affected.
Prevalence:
According to the Fragile X association of Southern California, Fragile X syndrome is the single most common inherited cause of mental impairment affecting 1 in 3600 males and 1 in 4000 to 6000 females with full mutation worldwide. Some studies also suggest that fragile X affects 1 in every 2000 males and 1 in every 4000 females of all races and ethnic groups. Studies have also revealed that 1 in 259 women of all races carry fragile X and could pass it to their children. The number of men who are carriers is thought to be 1 in 800 of all races and ethnicity. Carrier females have a 30% to 40>% chance of giving birth to a retarded male child and a 15 to 20% chance of having a retarded female.
Diagnosis/ prognosis:
The diagnosis of Fragile-X syndrome is made through the detection of errors in the FMR1 gene. Over 99% of individuals have a full mutant FMR1 gene. Tests used for diagnosis include chromosome analysis and various protein tests. Diagnosis is usually made when young, and there is no current cure for this illness. Early diagnosis of the syndrome call allow for therapeutic interventions like speech therapy, occupational therapy, psychotherapy and special education, that can considerably improve the quality of the patients' life.

What are monogenic diseases?? Cystic fibrous

Cystic fibrosis
Cystic Fibrosis is a genetic disorder that affects the respiratory, digestive and reproductive systems involving the production of abnormally thick mucus linings in the lungs and can lead to fatal lung infections. The disease can also result in various obstructions of the pancreas, hindering digestion. An individual must inherit two defective cystic fibrosis genes, one from each parent, to have the disease. Each time two carriers of the disease conceive, there is a 25 percent chance of passing cystic fibrosis to their children ; a 50 percent chance that the child will be a carrier of the cystic fibrosis gene; and a 25 percent chance that the child will be a non-carrier.
Prevalence:
The incidence of CF varies across the globe. Although it is severely underdiagnosed in Asia, existing evidence indicates that the prevelance of CF is rare. In the European Union 1 in 2000-3000 new borns is found to be affected by CF . In the United States of America the incidence of CF is reported to be 1 in every 3500 births.
Diagnosis/ prognosis:
People with CF have a variety of symptoms including: very salty-tasting skin; persistent coughing, at times with phlegm; wheezing or shortness of breath; an excessive appetite but poor weight gain; and greasy, bulky stools. Symptoms vary from person to person, in part, due to the more than 1,000 mutations of the CF gene, several of which have been identified and sequenced by researchers.The sweat test is the standard diagnostic test for CF. This simple and painless procedure measures the amount of salt in the sweat. A high salt level indicates CF. Although the results of this test are valid any time after a baby is 24 hours old, collecting a large enough sweat sample from a baby younger than 3 or 4 weeks old may be difficult. The sweat test can also confirm the diagnosis in older children and adults. If pancreatic enzyme levels are reduced, an analysis of the person's stool may reveal decreased or absent levels of the digestive enzymes (trypsin and chymotrypsin) or high levels of fat. If insulin secretion is reduced, blood sugar levels are high. Pulmonary function tests may show that breathing is compromised. Also, a chest x-ray may suggest the diagnosis. Relatives other than the parents of a child with cystic fibrosis may want to know if they're likely to have children with the disease. Genetic testing on a small blood sample can help determine who has a defective cystic fibrosis gene. Unless both parents have at least one such gene, their children will not have cystic fibrosis. If both parents carry a defective cystic fibrosis gene, each pregnancy has a 25 percent chance of producing a child with cystic fibrosis. During pregnancy, an accurate diagnosis of cystic fibrosis in the fetus is usually possible.
The severity of cystic fibrosis varies greatly from person to person regardless of age; the severity is determined largely by how much the lungs are affected. However, deterioration is inevitable, leading to debility and eventually death. Nonetheless, the outlook has improved steadily over the past 25 years, mainly because treatments can now postpone some of the changes that occur in the lungs. Half of the people with cystic fibrosis live longer than 28 years. Long-term survival is somewhat better in males, people who don't have pancreatic problems, and people whose initial symptoms are restricted to the digestive system. Despite their many problems, people with cystic fibrosis usually attend school or work until shortly before death. Gene therapy holds great promise for treating cystic fibrosis.
According to the CF Foundation's National Patient Registry, the median age of survival for a person with CF is currently 33.4 years. Only thirty years ago, a CF patient was not expected to reach adulthood. Many people even live into their fifties and sixties.
As more advances have been made in the treatment of CF, the number of adults with CF has steadily grown. Today, nearly 40 percent of the CF population is age 18 and older. Adults, however, may experience additional health challenges including CF-related diabetes and osteoporosis. CF also can cause reproductive problems - more than 95 percent of men with CF are sterile. But, with new technologies, some are becoming fathers. Although many women with CF are able to conceive, limited lung function and other health factors may make it difficult to carry a child to term.

What are monogenic diseases


What are monogenic diseases??
It is a pure genetic diseases are caused by a single error in a single gene in the human DNA. The nature of disease depends on the functions performed by the modified gene. The single-gene or monogenic diseases can be classified into three main categories:
Monogenic diseases result from modifications in a single gene occurring in all cells of the body. Though relatively rare, they affect millions of people worldwide. Scientists currently estimate that over 10,000 of human diseases are known to be monogenic. 1) Dominant
·         2) Recessive
·         3) X-linked
WE are aware from our undergraduate class that all human beings have two sets or copies of each gene called “allele”; one copy on each side of the chromosome pair. Recessive diseases are monogenic disorders that occur due to damages in both copies or allele. Whereas dominant diseases are monogenic disorders that involve damage to only one gene copy. But X linked diseases are monogenic disorders that are linked to defective genes on the X chromosome which is the sex chromosome.
However the  X linked alleles can also be dominant or recessive. These alleles are expressed equally in men and women, more so in men as they carry only one copy of X chromosome (XY) whereas women carry two (XX).
Monogenic diseases are responsible for a heavy loss of life. The global prevalence of all single gene diseases at birth is approximately 10/1000.

The common disease of our interst are 1) Thalassaemia 
2) Fragile X syndrome 3) Sickle cell anemia 4) Cystic Fibrosis .The other monogenic diseases are Haemophilia, Tay sachs disease &Huntington's disease


Thalassaemia is a blood related genetic disorder which involves the absence of or errors in genes responsible for production of haemoglobin, a protein present in the red blood cells. Each red blood cell can contain between 240 and 300 million molecules of haemoglobin. The severity of the disease depends on the mutations involved in the genes, and their interplay.
A haemoglobin molecule has sub-units commonly referred to as alpha and beta. Both sub-units are necessary to bind oxygen in the lungs properly and deliver it to tissues in other parts of the body. Genes on chromosome 16 are responsible for alpha subunits, while genes on chromosome 11 control the production of beta subunits. A lack of a particular subunit determines the type of thalassaemia (eg. a lack of alpha subunits results in alpha-thalassemia). The lack of subunits thus corresponds to errors in the genes on the appropriate chromosomes.
There can be various gradations of the disease depending on the gene and the type of mutations.
Prevalence:
The alpha and beta thalassaemias are the most common inherited single-gene disorders in the world with the highest prevalence in areas where malaria was or still is endemic. The burden of this disorder in many regions is of such a magnitude that it represents a major public health concern. For example in Iran, it is estimated that about 8,000 pregnancies are at risk each year. In some endemic countries in the Mediterranean region, long-established control programs have achieved 80-100% prevention of newly affected births.
Diagnosis/ prognosis:
Diagnosis of thalassaemia can be made as early as 10-11 weeks in pregnancy using procedures such as amniocentesis and chorionic villi sampling. Individuals can also be tested for thalassaemia through routine blood counts. Thalassaemic patients may have reduced fertility or even infertility. Early treatment of thalessaemia has proved to be very effective in improving the quality of life of patients. Currently, genetic testing and counselling, and prenatal diagnosis play an increasingly important role in informing individual as well as professional decisions around the prevention, management and treatment of this disease.

Between beta Thalassaemia Trait and HBE trait which one relatively easy to manage in pregancy period/ labour period??


. What are the types of globin chains attached to haem pigment ?? We know that haemoglobin is a terameric protein, composed of two kinds of globin chains.  Therefore there are total four globin chains are attached to each haem molecule. Thalassaemia by definition is quantitative diminution of synthesis of one or two type’s globin chains. But by haemoglobinopathies we understand there are structurally abnormal globins and such abnormal globin chains may affect either    β, α, γ or Õ chains. These are the four types of globin chains. When to think of abnormal haemoglobin after going through peripheral smear? Or say Thalassemia??
1)                       Microcytosis disproportionate to the degree of anemia. 2) then one should enquire any positive family history or lifelong personal history of microcytic anemia 3) Abnormal red blood cell morphology with microcytes acanthocytes and target cells
Q. What to diagnose B thalassemia?? Ans:-  In B thalassemia elevated levels of hemoglobin A2 or F
General Considerations : The thalassemia are hereditary disorders characterized by reduction in the synthesis of globin chains. Reduced globin chain synthesis causes reduced hemoglobin synthesis and eventually produces a hypochromic microcytic anemia because of defective hemoglobinization of red blood cells. Thalassemias can be considered among the hypoproliferative anemias the hemolytic anemias and the anemias related to abnormal hemoglobin since all of these factors play a role in pathogenesis.
  
. .Q. 2: What are the three usual types of globin  chains are observed in persons who carry near normal globin moiety?? Ans:   in adults there are normally  three kinds of globin chains: and amount of each globin varies person to person but the usual range is as follows:- is HbA0  (α-2,  β -2 chains    )  and this is  comprises about 95-97% of all globin moiety in a haemoglobin molecule. :  HbA2 by contrast have following globin pattern (α-2 and Õ2 chains) and it comprises     normally  about 2-3% of all  globins in haemoglobin. Lastly (third variety) is   HbF  (comprises of  two α-chains  and 2  γ chains ). HbF  is < 2% of all globin  chains. When only one a- globin chain is present the patient has hemoglobin H disease. This is a chronic hemolytic anemia of variable severity. Physical examination will reveal pallor and splenomegaly. Although affected individuals do not usually require transfusions they may do so during periods of hemolytic exacerbation caused by infection or other stresses. When all four a-globin genes are deleted the affected fetus is stillborn as a result of hydrops fetalis.


What is the difference between Thalassaemia & Haemoglobinopathies:-:-We all know that: the thalassemia are due to a quantitative defect in the globin chain production. Haemoglobinopathies result from a) structural defect in the globin gene, c)  whereas the average frequency of Hb-S and Hb-D is 4.3% and 0.86%, respectively in Indian population . HbS, HbE, and Hb D are prevalent in India..
The genetics of normal goblin synthesis: What about alpha chains? Such chains are governed by 4 genes all of them are located at Chromosome 16. What about beta chains production?: Such are controlled only by 2 genes which are located at Chromosomes 11. Beta thalassaemia is a mutation disorder.(Alpha thalassaemia is a deletion disorders). Normal adult hemoglobin is primarily hemoglobin A which represents approximately 98% of circulating hemoglobin. Hemoglobin A is formed from a tetramer two a chains and two B chains – and can be designated a2 B2 . Two copies of the a globin gene are located on chromosome 16 and there is no substitute for  a globin in the formation of hemoglobin . The B globin gene resides on chromosome 11 adjacent to genes encoding the B like globin chains g and y . The tetramer of a2 g2 forms hemoglobin A2 which normally comprises 1-2 % of adult hemoglobin . The tetramer a2 y2 forms hemoglobin F which is the major hemoglobin of fetal life but which comprises <1% of normal adult hemoglobin .

Hemoglobin chain disorders are principally tow kinds Type A disorders are quantitative in nature but no structural defect in globin synthesis (thalassemia group of disorders) : There is no abnormality in structure of globin chains. All the four globin chains are structurally normal but the production rate of any one is at slower speed at factory (Quantitatively low globin chains usually one chain is affected) . It is a quantitative defect of the globin synthesis and are due to genetic defect. .Such genetic defect (inactivation-mutant genes )  may involve either α,  β or γ β chains .By contrast the beta chain of globin  manufacturing:-There are two Varity of  β thalassemia  :    β thalassemia major implies both the genes  designated for    β chain  synthesis are defective (derived one from each parent) and   β thalassemia minor implies only one   gene  entrusted with synthesis of   β globin  is defective .
Thalassaemia Diagnostic dilemma:-Confirmation   of diagnosis must be done in conjunction with 1) Parental Screening, 2)  DNA  study  &  3) blood picture B-12   deficiency .4)  Severe Iron  deficiency can   lead to borderline HbA2’s . The Hb A2 results   must be repeated after correcting the   Iron  deficiency.  Normally a man/ woman of beta Thalassemia minor will exhibit HbA of 80-95%: HBA2 of 4-10% and HBF will be usually in the range of 1-5%.. In cases of all thalassaemia  Family studies must be done  to  confirm  the compound heterozygous  conditions  of thalassaemia &  a haemoglobinopathies   together  or when the  haemoglobinopathies coexist. The results    cannot be suggestive of a particular diagnosis  if the sample  was analyzed    following   a blood transfusion , Most haemoglobin variants   are clinically silent. In beta thalassemia carrier 1) to supplement full dose of F acid2) If ferritin is low then oral Fe is indicated but by and large Blood transfusion is contraindicated,. Unless Hb is < 8Gm near term.

What about HBE prevalence: - This  gene frequency in north eastern regions of India has been reported to be 10.9%. In a study, the prevalence of sickle cell disorders was found to vary from 2.4% to 5.6% among the tribes of Orissa in eastern India / in central India, the prevalence of sickle cell disorders was observed to be 5.7% among children.
What about the terminology of HPLC? Hemoglobin separates into major and minor hemoglobin’s when subjected to CE-HPLC. The order of elution of the various components is HbA1a, HbA1b, Hb, LA1c/CHb-1, LA1c/CHb-2, HbA1c, P3 (Hb component), HbA0, and HbA2. The minor hemoglobin’s A1a, A1b, A1C, F1, and the P3 component are posttranslational modifications of the globing chains. HbA2, a minor hemoglobin, however, is composed of two alpha and two delta chains. HbA0 and Hb are the major hemoglobin’s in a normal  population.
What about HbA2  level ?? What is β-thalassemia trait?  An elevated HbA2 with an average value of about 5%, along with microcytic hypo chromic indices, is characteristic of β-thalassemia trait in β-thalassemia major, in addition to a markedly microcytic hypo chromic blood picture; there are elevated HbA2 and elevated Hb ranging from 10 to 90% .He trait is diagnosed by the presence of a high HbA2 (E+A2), approximately 30% Homozygous He patients have approximately 90% HbE+A2 with minor elevation of Hb . HbE+A2 levels of 40–60% with marked elevation of Hb are seen in He-β-thalassemia Hobs is around 40% in sickle cell trait, 90–95% in sickle cell anemia’s (which varies inversely with Hb proportion), and less than 50% in sickle β-thalassemia .Approximately less than 50% of abnormal hemoglobin is seen in Hb traits
The present study highlights the detection of the haemoglobinopathies and thalassemia by CE-HPLC.


Type B disorders are called Haemoglobinoathies? HbE Disorders (E Trait, EE, E β-Thalassemia)
Comparing all the HbE disorders, it is seen that the lowest hemoglobin as well as the highest proportion of HbF is seen in HbE β-thalassemia The single case of HbSE disorder had a hemoglobin of 10.1 gm%, thalassemic indices with MCV of 71fl, MCH of 23.1 pg, 36.7% of HbA2+HbE, and 2.8% of HbF.

Q. 3: What are the different kinds of haemoglobinopathies??  There is mutation of any one of the total 400 genes involved in the synthesis of globin chains.   Haemoglobin variants are due to manufacture of abnormal globins usually one chain is affected. Such structurally abnormal  haemoglobin are collectively called as Haemoglobinopathies .Most important example is sickle cell disease, trait and  HbC  diseases, Hb C disease, HbE trait, (20-35% HBE structurally).However HBE trait may be very rarely combined with beta trait when it should be investigated as Thalassaemia major.(prenatal testing like Thalassaemia  major is important & recommended).
In sickle cell trait:- There is mutation of any one of the total 400 genes involved in the synthesis of globin chains.  It is due to substititution of 1 amino acid for another one. Sometimes it may be due to deletion of a portion of amino acid sequence: He/ She may complain of painless haematuria. Such trait has no anemia and normal RBC morphology but higher rate of UTI / Splenic infarct.
What about Sickle Cell disease? It is basically a chr hemolytic anemia and one glutamic acid is replaced by valine at position of 6 of the beta globin  chain. HBs? Beta thalassaemia are not uncommonly present in Indian population (South India in particular) and in Africa. Mild jaundice, cholelithiasis, splenomegaly are common as is retinopathy and stroke.. Normocytic normochromic anemia with target cells, sickled cells and ovalocytes.

.
Which method may be best used for detection of structural abnormality of globin chains of Haemoglobin?? Ans:- Most haematologist believe that  cation exchange-high performance liquid chromatography (CE-HPLC) is increasingly being used as a first line of investigation for haemoglobinopathies and thalassemia. Together with a complete blood count, the CE-HPLC is effective in categorizing haemoglobinopathies as traits, homozygous disorders and compound heterozygous disorders.

What is the prevalence  of different thalassaemia and Haemoglobinopathies  in India?? Ans: The commonest disorder in  India varies from state to state. In one study concentrating chiefly South Indian population it was observed that  1)  β-thalassemia trait (37.9%),  2) HbE trait (23.2%), 3) homozygous HbE (18.9%), 3)  HbS trait (5.3%), 4) HbE β-thalassemia (4.6%), 5) HbS β-thalassemia (2.5%) ,6)  β-thalassemia major (2.3%),7)  HbH (1.6%), 8)  homozygous HbS (1.4%), and HbD trait (0.7%).



When we wil designate as    Thalassemia Trait?? The Thalassemias are described as trait when there are laboratory features without significant clinical impact and  when there is a red blood cell transfusion requirement or other moderate clinical impact and major when the disorder is life threatening.
What is  α  Thalassaemia ?? Ans: a-Thalassemia is due primarily to gene deletion causing reduced a-globin chain synthesis. Since all adult hemoglobins are a containing a – thalassemia produces no change in the percentage distribution of hemoglobins A,  A2 and F. In severe forms of a- Thalassemia excess B chains may form a B 4 tetramer called hemoglobin H.
What causes  β Thalassemia  ?? B-Thalassemias are usually caused by point mutations rather than deletions. These mutations result in premature chain termination or in problems with transcription of RNA  and ultimately result in reduced or absent B-globin chain synthesis . The molecular defects leading to B- thalassemia are numerous and heterogeneous. Defects that result in absent globin chain expression are termed B whereas those causing reduced synthesis are termed B. The reduced B-globin chain synthesis in B-thalassemia results in a relative increase in the percentages of hemoglobins A2 and F compared to hemoglobin A as the B like globins substitute for the missing B chains. In the presence of reduced B chains the excess a chains are unstable and precipitate leading to damage of red blood cell membranes. This leads to both intramedullary and peripheral hemolysis. The bone marrow becomes hyperplastic under the drive of anemia and ineffective erythropoisies resulting from the intramedullary destruction of the developing erythroid cells. In cases of severe thalassemia the marked expansion of the erythroid element n the bone marrow may cause severe bony deformities osteopenia and pathologic fractures.
How do we diagnose Beta Thalassaemia?? What may be preliminary Clinical Findings?
A.                    Symptoms and Signs
The a- thalassemia syndromes are seen primarily in persons from southeast Asia and China and less commonly in blacks. Normally adults have four copies of the a-globin chain. When three a- globin genes are present the patient is hematologically normal. When two a- globin genes are present the patients is said to  have a thalassemia trait one form of thalassemia minor. These patients are clinically normal and have a normal life expectancy and performance status with a mild microcytic anemia.

Global Location: Zone of high prevalence:-B-Thalassemia primarily affects persons of Mediterranean origin and to a lesser extent Asians and blacks. Patients homozygous for B- thalassemia have thalassemia major . Affected children are normal at birth but after 6 months when hemoglobin synthesis switches from hemoglobin F to hemoglobin A, develop severe anemia requiring transfusion. Numerous clinical problems ensue including growth failure bony deformities hepatosplenomegaly and jaundice. The clinical course is modified significantly by transfusion therapy  but the transfusional iron overload results in a clinical picture similar to hemochromatosis with heart failure cirrhosis and endocrinopathies usually after more than 100 units of red blood cells. These problems develop because of the body’s inability to excrete the iron from transfused red cells. Before the application of allogeneic stem cell transplantation and the development of more effective forms of iron chelation death from cardiac failure usually occurred between the ages of 20 and 30 years . This has been profoundly changed by the early application of transplantation .
What do U man by homo/heterozygosis?? Patients homozygous for a milder form of B- thalassemia have Thalassaemia intermedia. These patients have chronic hemolytic anemia but do not require transfusions except under periods of stress. They also may develop iron overload because of periodic transfusion. They survive into adult life but with hepatosplenomegaly an bony deformities minor and a clinically insignificant microcytic anemia.
Is it possible to diagnose by prenatal methods? When such tests become necessary? What is these nionivaaive method now available for diag Thal major( Prenatal diagnosis is available and genetic counseling should be offered and the opportunity for prenatal diagnosis discussed What are the informations we gather from cell free DNA (foetal cells citculatimg in maternal blood) ?? .
What do U expect if U send the blood to A REPUTED LAB? Have lab reports of this indoor pt  been supplied by te  invigilators to you, my  dear candidate?? Have seen the Laboratory Findings already done?
What is α-Thalassemia trait- Patients with two a- globin genes have mild anemia with hematocrits between 28% and 40% . The MCV is strikingly low despite the modest anemia and the red blood count is normal or increased. The peripheral blood smear shows microcytes hypochromic occasional target cells and acanthocytes . The reticulocytes count and iron parameters are normal. Hemoglobin electrophoresis will show no increase in the percentage of hemoglobin A2 or F and no hemoglobin H  a- thalassemia trait is thus usually diagnosed by exclusion . Genetic testing to demonstrate a- globin gene deletion is available only in research laboratories.
2 A very rare diseases  is HB H diseases? Have U heard the name of it?? Hemoglobin H disease- These patients have a more marked hemolytic anemia with hematocirts between 22% and 32%.The MCV is remarkably low and the peripheral blood smear is markedly abnormal with hypochromia microcytosis target cells and poikilocytosis. The reticulocye count is elevated . Hemoglobin electdrophoresis will show the presence of fast migrating hemoglobin which comprises 10-14 % of the hemoglobin. A peripheral blood smear can be stained with supravital dyes to demonstrate the presence of hemoglobin H.
 What U do know about β-Thalassemia minor-not an uncommon condition in N E India??  – As in a thalassemia trait these patients have a modest anemia with hematocrit between 28% and 40%  . The MCV ranges from 5 to 75 ft and the red blood cell count is normal or increased. The peripheral blood smear is mildly abnormal with hypochromia  Microcytosis and target cells. In contrast to a – thalassemia basophilic stippling may be present. The reticulocytes count is normal or slightly elevated. Hemoglobin electrophoresis may show an elevation of hemoglobin A2 to 4-8% and occasional elevations of hemoglobin F to 1-5%
4:-Thalassemia major – B- Thalassemia major produces severe anemia and without transfusion the hematocrit showing severe poikilocytosis hypochromia microcytosis target cells basophilic stippling and nucleated red blood cells. Little or no hemoglobin A is present Variable amounts of hemoglobin A2 are seen and the major hemoglobin present a hemoglobin F.
Thal trait?  Treatment
Patients with mild thalassemia require no treatment and should be identified so that they will no be subjected to repeated evaluations and treatment for iron deficiency. Patients with hemoglobin H disease should take folate supplementation and avoid medicinal iron and oxidative drugs such as sulfonamides. Patients with severe thalassemia are maintained on a regular transfusion schedule and receive folate supplesmentation. Splenectomy is performed f hypersplensim causes a marked increase in the transfusion requirement . Patients with regular transfusion requirements should be treated with iron chelation in order to prevent life limiting organ damage from iron overload. Subcutaneous infusion of deferoxamine has largely been replaced by the oral agent deferasirox.
What about Marrow Transplantation?? Allogenic bone marrow transplantation is the treatment of choice for B- thalassemia major. Children who have not yet experienced iron overload and chronic organ toxicity do well with long term survival in more than 85% of cases.
General Considerations.
 U are doing well . Wee the examiners are happy with your answer. But can U tellus what do U mean by the term  sideroblastic anemia ?? Sideroblastic anemias are a heterogeneous group of disorders in which hemoglobin synthesis is reduced because of failure to incorporate heme into protoporphyrin to form hemoglobin. Iron accumulates particularly in the mitochondria. The disorder is usually acquired it is most often a subtype of myelodysplasia . Other causes include chronic alcoholism and lead poisoning.
 What are the Clinical Finding  of Sideroblastic anemias?? Any idea dear examinee??
Patients have no specific clinical features other than those related to anemia. The anemia is usually moderate with hematocrits of 20-30% but transfusions may occasionally be required. Although the MCV is usually normal or slightly increased it may occasionally be low, leading to confusion with iron deficiency. However, serum iron level is elevated and transferrin is high. The peripheral blood smear characteristically shows a dimorphic population of red blood cells, one normal and one hypochromic. In cases of red poisoning, coarse basophilic stippling of the red cells is seen and the serum lead levels will be elevated. The diagnosis is made by examination of the bone marrow. Characteristically, there is marked erythroid hyperplasia, a sign of ineffective erythropoieis (expansine of the erythroid compartment of the bone marrow that dose not result in the production of reticulocytes in the peripheral blood ). The Prussian blue iron stain of the bone marrow shows a generalized increase in iron stors and the presence of ringed sideroblasts, which are cells with iron deposite encircling the red cell nucleus. Occasionally, the anemia is so severe that support withtransfusion is required. These patients usually do not respond will to erythropoietin therapy, especially when transfusion requirements are significant


Wednesday, 29 April 2020

Asynchronous growth of follicles-How to rectify

Asymmetric Follicular Growth. /Asynchronous follicular response. Prevent premature rise of FSH in previous cycle at day 23/ 25 I e the time what scientists call
luteofollicular transition by OCP, agonist, only progesterone in pretreatment cycle.
Top of Form


Comments
·         Q.1. What is the cause/ causes of nonuniform growth of follicles in natural cycles / Stimulated cycles (non-ART/ ART cycles ) ? Ans:--Causes are unrecognized raised LH, androgens, high progesterone or high oestrogen in early follicular phase, All such mild elevations can lead to and can disturb symmetrical follicular growth & thereby adversely affect oocyte too.
Q.2:
What is the overall outcome?? Ans: asymmetrical follicular profile or non uniform growth can in prevented in a large majority of good responder by correcting the adverse offending hormonal imbalance but such may not be possible in poor responders.
Q. 2B What is the definition of Asymmetrical follicular growth:?? Ans: When lead follicle are larger than 4 mm of rest of majority follicles..
Q. 3.
What is nonendocrine causes of such an abnormal /asynchronous follicular response : Ans: Scientists believe that It is the differential fsh threshold of antral and preantral follicles. Those follicles which are having least threshold( more responsive even in low dose of FSH) start growing earlier and at a faster speed .
Q. 4:
What may be solutions?? Ans: There are three ways to synchronizes follicles. If no obvious endocrine abnormality is detected / established, as is often the case then intelligent manipulation by some drugs in pre-treatment(cycle prior to proposed stimulation) is most relevant and such have to be designed and implemented intelligently preferably by an ART specialist of long experience : It is the luteofollicular transition when we have to react to achieve synchronous growth in next cycle .It is no point to rectify when asynchrony is already in progress(reinstatement cycle) . The very basic principle is that we want to prevent premature appearance or rise FSH rise of luteofollicular transition i.e. very early rise of FSH in later part of previous cycle (pretreatment cycle). This will almost always lead to asynchronous follicles. This have been variously targeted by 1) Pretreatment OCP 1 month/ 2 months 2) Only oestrgen to decrease FSH 3) Only progesterone form day 16 Primolut-N 1 tds in previous cycle for 10 days .It is needless to mention that such pre treatment cycle should be covered by barriers.
Q.5
How can it be prevented inj the indexed cycle? Say, sometimes on stimulation day 6 in CC/ Letroz. In such asymmetric growth-- one can view two/ three follicles already 16 mm while rest all follicles are lagging in the sense that they are very small .In such a set up how optimally one can proceed for further stimulation a) in that cycle without cancellation b) what precautions or adjustments should be made in next cycle-so that uniform /homogenous F growth are reasonably assured??
?
Q. 6 . What is the minimum size of follicle at which trigger can be given and at te same time achieve mature eggs expected?.Ans:-Mature oocytes can be aspirated by ovum pick up when any follicle is more than 14 mm . They usually harbour mature oocytes
Unless it is an empty follicular syndrome discussed on 29-04-20.

Solution 1: Agonist started on previous luteal phase itself will synchronizes the follicle. That is the one of the reason why many ART specialists are still fan of long agonist protocol. But long agonist protocol despite the fact that it is costly, bothersome for couple, requires , frequent follow up & blood testing. Agonist started on previous luteal phase itself will almost always synchronize the follicles.
Solution 2:--One has to control hyperinsulinemia which is often associated with asymmetrical follicular growth:.
Solution 3. For batch IVF if one is using long agonist protocol then this Shoud not be problem. IN that case estrogen progesterone priming before down regulating should solve problem. When more than 50 % crosses 14-15 mm also do give consideration to perifollicular Doppler flow as well as endometrial scoring then can plan trigger in ART cycles.
Trigger-When? To administer trigger when more than 50% growing follicles have crossed 14 mm.
What about in antagonist cycle??
Pretreatment with estradiol in antagonist cycle
In agonist cycles.
In agonist cycles- 1) coasting for 4-5 days and simultaneously use 2) testosterone gel till trigger, continue agonist, 3) resume gonadotropins after 5 days, it will help in catching up growth of less than 10.mm sized follicles.
Prophylaxis :-1) testosterone gel What's the dose of testosterone gel ?It is :-25 mg daily .
2) Estradiol pretreatment before stimulation or before trigger

Bottom of Form